Press release
Atrial Fibrillation Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Atrial Fibrillation Treatment Landscape. Click here to read more @ Atrial Fibrillation Pipeline Outlook [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Atrial Fibrillation Pipeline Report
* In July 2025, Biosense Webster Inc . announced a STELLAR study is a pivotal, prospective, multicenter, single-arm, clinical evaluation of the Multi-Electrode RF Balloon catheter. The study will evaluate the safety and effectiveness of the Multi-Electrode RF Balloon catheter used for ablation in patients with paroxysmal atrial fibrillation (PAF).
* In July 2025, Medtronic Cardiac Rhythm and Heart Failure conducted a study is to demonstrate the efficiency on AT / AF prevention and termination of a new algorithm contained in the Medtronic AT500 Antitachycardia device in patients with conventional pacemaker indications.
* DelveInsight's Atrial Fibrillation pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Atrial Fibrillation treatment.
* The leading Atrial Fibrillation Companies such as Thryv Therapeutics Inc., Janssen Research & Development LLC, HUYABIO International LLC., Milestone Pharmaceuticals Inc., Anthos Therapeutics Inc., Bayer and others.
* Promising Atrial Fibrillation Pipeline Therapies such as Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.
Stay informed about the cutting-edge advancements in Atrial Fibrillation Treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Atrial Fibrillation Clinical Trials Assessment [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Atrial Fibrillation Emerging Drugs Profile
* Abelacimab: Anthos Therapeutics, Inc.
Abelacimab is a novel, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease. As a fully human monoclonal antibody, abelacimab is not metabolized via the cytochrome P450 system or as a substrate for P-glycoprotein, meaning the risk for drug-drug interactions is very unlikely. There is also no need to adjust the dose based on age or renal/hepatic status and it can be safely co-administered with antiplatelet agents. Abelacimab is currently being evaluated in several ongoing Phase III clinical trials for patients at risk of dangerous arterial and venous clots, including those with atrial fibrillation and cancer associated thrombosis. In patients with atrial fibrillation, abelacimab is planned to be dosed subcutaneously once-monthly with an autoinjector to maintain near-complete inhibition in a chronic setting. It is also planned to be administered via an initial intravenous (IV) infusion for acute indications requiring immediate onset of action and then followed by subsequent monthly subcutaneous administration. Currently, the drug is in Phase III stage of its development for the treatment of Atrial Fibrillation.
* Etripamil: Milestone Pharmaceuticals Inc.
Etripamil is a fast-acting, intranasal calcium channel blocker developed for the acute management of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). Designed for self-administration, it is delivered via a nasal spray, allowing for quick absorption through the nasal mucosa, with onset of action typically within 10 minutes. Etripamil acts rapidly to control heart rate by blocking calcium influx into cardiac cells, helping to slow conduction through the atrioventricular (AV) node. Its short duration of action may reduce the risk of long-term side effects commonly associated with continuous use of traditional antiarrhythmic medications, making it a convenient and potentially safer option for managing sudden AFib episodes. Currently, the drug is in Phase II stage of its development for the treatment of Atrial Fibrillation.
* THRV-1268: Thryv Therapeutics, Inc.
THRV-1268 is a novel and potent inhibitor of the Serum Glucocorticoid Kinase 1 (SGK1). SGK1 is a PI3-kinase-dependent kinase with its expression and activation regulated by several metabolic signaling pathways that are crucial in cardiometabolic diseases. Thryv Therapeutic's first SGK1 inhibitor, LQT-1213, repeatedly demonstrated reductions in QTc interval in pre-clinical studies and in patients with the genetic and acquired Long QT Syndrome. SGK1 has been implicated in various pathological conditions, including QTc prolongation, arrhythmias, fibrosis, and heart failure. SGK1 dysfunction is also linked to cardiometabolic stressors such as obesity and hypertension, which are common comorbidities in heart failure. Genetic and pharmacological inhibition of SGK1 has been demonstrated to have a protective effect in a mouse model of obesity-related atrial fibrillation. In several preclinical models of heart failure, THRV-1268 mitigated the development of heart failure and fibrosis, and reduced heart failure biomarkers associated with adverse changes in hemodynamic and functional cardiovascular outputs. These findings demonstrate the potential of SGK1 inhibition in addressing the pathogenesis of heart failure and related cardiometabolic conditions, including atrial fibrillation. Currently, the drug is in Phase I stage of its development for the treatment of Atrial Fibrillation.
The Atrial Fibrillation Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
* Atrial Fibrillation Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.
Get a detailed analysis of the latest innovations in the Atrial Fibrillation pipeline. Explore DelveInsight's expert-driven report today! @ Atrial Fibrillation Unmet Needs [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Atrial Fibrillation Companies
Thryv Therapeutics Inc., Janssen Research & Development LLC, HUYABIO International LLC., Milestone Pharmaceuticals Inc., Anthos Therapeutics Inc., Bayer and others.
Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Atrial Fibrillation Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Atrial Fibrillation Treatment by visiting our website. Stay informed about how we're transforming the future of Cardiovascular Diseases @ Atrial Fibrillation Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Atrial Fibrillation Pipeline Report
* Coverage- Global
* Atrial Fibrillation Companies- Thryv Therapeutics Inc., Janssen Research & Development LLC, HUYABIO International LLC., Milestone Pharmaceuticals Inc., Anthos Therapeutics Inc., Bayer and others.
* Atrial Fibrillation Pipeline Therapies- Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.
* Atrial Fibrillation Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Atrial Fibrillation Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Atrial Fibrillation Pipeline on our website @ Atrial Fibrillation Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Atrial Fibrillation: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Atrial Fibrillation- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Abelacimab: Anthos Therapeutics, Inc.
* Mid Stage Products (Phase II)
* Etripamil: Milestone Pharmaceuticals Inc
* Early Stage Products (Phase I)
* THRV-1268: Thryv Therapeutics, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Atrial Fibrillation Key Companies
* Atrial Fibrillation Key Products
* Atrial Fibrillation- Unmet Needs
* Atrial Fibrillation- Market Drivers and Barriers
* Atrial Fibrillation- Future Perspectives and Conclusion
* Atrial Fibrillation Analyst Views
* Atrial Fibrillation Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atrial-fibrillation-pipeline-outlook-report-2025-key-10-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atrial Fibrillation Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4125276 • Views: …
More Releases from ABNewswire
Total Joy Homecare Responds to Surging Demand for Senior Health Care Services in …
Total Joy Homecare expands services to meet growing Houston demand for in-home senior care, offering non-medical support that helps families maintain independence and dignity at home.
Houston's rapidly aging demographic has prompted local care provider Total Joy Homecare to expand its comprehensive support services, addressing the critical need for quality senior health care services [https://maps.app.goo.gl/hUcW1N7qWy5EdHJs5] throughout the Greater Houston area. The company's response comes as families increasingly seek reliable alternatives to…
Texas Company Introduces On-Site Carrier Repair Services to Reduce Fleet Downtim …
Texas Reefer Solutions introduces mobile carrier repair services in Dallas, revolutionizing how transportation fleets handle refrigeration breakdowns by providing on-site professional repairs, eliminating route deviations, and reducing cargo-threatening delays.
The transportation industry faces a significant challenge when refrigerated trucks require repairs, often forcing drivers to deviate from critical routes and schedules. Texas Reefer Solutions has emerged as a game-changing solution, introducing mobile carrier repair services [https://maps.app.goo.gl/P6nfg5WF7sckR7aZ8] that bring professional technicians directly…
Family Therapy in Birmingham: How the Right Therapist Can Transform Relationship …
Family therapy in Birmingham helps families improve communication, resolve conflict, and build stronger bonds. With the support of a qualified therapist near you, therapy creates a safe space to share, heal, and reconnect. Whether you're searching for therapy near me or counselling for your family, Phinity Therapy offers guidance for lasting change.
Families are the foundation of our lives. They provide love, support, and connection, but they can also be the…
Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Atrial
Rising Cardiovascular Disease Rates Drive Growth In Atrial Flutter: A Key Driver …
The Atrial Flutter Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Atrial Flutter Market Size and Its Estimated Growth Rate?
In recent times, the market size for atrial flutter has seen swift growth. The market evaluation is expected to rise from $19.92…
Elevated Prevalence Of Atrial Fibrillation Fuels Growth In The Left Atrial Appen …
What Are the Projected Growth and Market Size Trends for the Left Atrial Appendage Closure Device Market?
The left atrial appendage closure device market will grow from $1.67 billion in 2024 to $2 billion in 2025, at a CAGR of 19.5%. The growth is attributed to the rising prevalence of atrial fibrillation, advancements in stroke prevention strategies, clinical evidence and research, minimally invasive alternatives, and a preference for non-pharmacological options.
The left…
Atrial Fibrillation Surgery Devices Market - Restoring Rhythm, Transforming Live …
Newark, New Castle, USA: The "Atrial Fibrillation Surgery Devices Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Atrial Fibrillation Surgery Devices Market: https://www.growthplusreports.com/report/atrial-fibrillation-surgery-devices-market/8777
This latest report researches the…
Atrial Fibrillation Market - Unveiling the Path to a Steady Heart: Advancements …
Newark, New Castle, USA - new report, titled Atrial Fibrillation Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Atrial Fibrillation market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Atrial Fibrillation market. The report offers an overview of the market, which…
Atrial Fibrillation Market Insights, Forecast to 2030
The report extensively examines the global Atrial Fibrillation market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Atrial Fibrillation . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
Atrial Fibrillation Stroke Treatment Market Segmentation By Atrial Fibrillation …
The arrhythmia problem occurs due to irregular heartbeats which can cause atrial fibrillation stoke. The irregular manner (increase pattern or lower pattern of heart beats) of heart beating pattern can cause atrial fibrillation stroke. The atrial fibrillation stroke causes major problem of heart and increase heart related problem. The patient which are suffering from atrial fibrillation effect two chamber of heart and atria present below the heart will lead to…
